Showing results (161-170 of 234) with videos related to
Sort By:
Pageof 24
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.Nature Communications|January 9, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancerGillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound TrialJoaquin Mateo, Johann S de Bono, Karim Fizazi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.Pageof 24